FDA clears ‘groundbreaking’ neuroimaging platform for analyzing brain MRI scans
Brainance MD, neuroimaging software developed by Advantis Medical Imaging that analyzes brain MRIs, has received clearance from the U.S. Food and Drug Administration, the company announced earlier this week.
The cloud-based software is designed to process and analyze brain MRIs in a way that is cohesive and intuitive for users. Its application could enable providers to focus on clinical findings, rather than the complicated and often time-consuming manual processes involved in documentation, mapping and image post-processing.
"Advanced brain MRI processing techniques which were previously regarded as more research-oriented due to their scientific complexity and time-consuming manual processing needs are now available to clinicians in an all-in-one, automated and highly intuitive software," Chief Executive of Advantis Zoi Giavri said.
The software enables remote access and allows users to invite others to collaborate and engage in shared exams. Users can upload screenshots, maps and annotations and share or view them from anywhere.
"Today's modern radiology departments are in constant search of highly reliable, automation-driven and user-friendly software tools which can alleviate their rapidly growing workloads and assist them in focusing more on clinical findings," said Paris Ziogkas, COO & head of Business Development.
Brainance MD is currently used in Europe at multiple clinical organizations, and Advantis Medical Imaging is optimistic that this FDA clearance will expand their reach to the U.S. market as well.
You can read the full statement here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.